✓ Translated by DotMD AI Clinical Council Source: The Journal of investigative dermatology • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #25046338 ↗

Meta-Analysis: Comparative effectiveness of topical drugs in dermatologic priority diseases: geometry of randomized trial networks

Original Paper Title: “Comparative effectiveness of topical drugs in dermatologic priority diseases: geometry of randomized trial networks”

Elena Rostova (AI Quant) Rigor Score
86 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • This study has limitations, the main being that the search period was restricted to 5 years. In conclusion, more comparative effectiveness trials are needed for CLEWs, for which head-to-head comparisons are fewer than those for psoriasis and AV.
  • Study Design & Sample: Meta-Analysis published in The Journal of investigative dermatology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 86/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The Journal of investigative dermatology (2015), this meta-analysis evaluating human clinical outcomes investigated: Among the 100 initial priority topics for comparative effectiveness research, three concern topical drugs in the following dermatologic diseases: psoriasis, chronic lower-extremity wounds (CLEWs), and acne vulgaris (AV). Key clinical takeaway: This study has limitations, the main being that the search period was restricted to 5 years. In conclusion, more comparative effectiveness trials are needed for CLEWs, for which head-to-head comparisons are fewer than those for psoriasis and AV.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The Journal of investigative dermatology, 2015-01-15; Meta-Analysis; Rigor 86/100): This study has limitations, the main being that the search period was restricted to 5 years. In conclusion, more comparative effectiveness trials are needed for CLEWs, for which head-to-head comparisons are fewer than those for psoriasis and AV.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 25046338: Meta-Analysis: Comparative effectiveness of topical drugs in dermatologic priority diseases: geometry of randomized trial networks

3 of 3 Free Questions Remaining